Table 3 Overview of anti-calcitonin-gene related (CGRP) (receptor) peptide monoclonal antibodies in order by target and alphabetical
From: Therapeutic novelties in migraine: new drugs, new hope?
Drug | Target | Administration | Interval between administrations | Status |
|---|---|---|---|---|
Erenumab (AMG-334) | Receptor | Subcutaneous injection | 4 weeks | FDA approved; phase III clinical trials |
Eptinezumab (ALD403) | Ligand | Intravenous infusion | 12 weeks | Phase III clinical trials |
Fremanezumab (TEV-48125) | Ligand | Subcutaneous injection | 4 or 12 weeks | FDA approved; phase III clinical trials |
Galcanezumab (LY2951742) | Ligand | Subcutaneous injection | 4 weeks | FDA approved; phase III clinical trials |